@article{b1a4d92801fd46beb0e5219989d5b99f,
title = "International Primary Care Respiratory Group (IPCRG) Guidelines: Management of Chronic Obstructive Pulmonary Disease (COPD)",
abstract = "COPD is a common and under-diagnosed disease which is increasing in prevalence worldwide. A more aggressive and optimistic approach must be adopted towards its management in primary care. This IPCRG Guideline on the management of COPD in primary care is fully consistent with GOLD guidelines. It highlights the goals of COPD treatment and the need for spirometric testing to make the diagnosis. It covers the classification of the disease according to disease severity, non-pharmacologic therapy including smoking cessation, avoidance of risk factors, patient education, pharmacologic therapy including the use of oxygen treatment, the management of exacerbations, the role of pulmonary rehabilitation, and the need for monitoring and ongoing care for COPD patients.",
keywords = "COPD, Classification, General practice, Guideline, Management, Primary care, Spirometry, Treatment",
author = "David Bellamy and Jacques Bouchard and Svein Henrichsen and Gunnar Johansson and Arnulf Langhammer and Jim Reid and {Van Weel}, Chris and Sonia Buist",
note = "Funding Information: Dr A. Langhammer has no shares in pharmaceutical companies or tobacco industry. He has received speakers honoraria for speaking at sponsered meeting for GSK, AZ, MSD, Boehringer Ingelheim. He has received honaria for advisory panel work for AZ, Pfizer and MSD. He was project leader of a substudy of the Nord-Tr{\o}ndelag Study (HUNT2) focusing on obstructive lung diseases This study was funded by AZ through a contract between the Medical Director of AZ and the Director of the National Institute of Public Health. Dr Langhammer was employed by the National Institute of Public Health during the data collection period. Funding Information: Professor A.S. Buist has served on advisory boards for GlaxoSmithKline, ALTANA, Schering Plough and Merck and donates most of her honoraria to the ATS; she has participated in COPD workshops funded by AstraZeneca and GlaxoSmithKline: and is Scientific Director for the Burden of Obstructive Lung Disease (BOLD) an initiative that receives unrestricted educational grants to the Kaiser Permanente Center for Health Research from Boehringer Ingelheim, Pfizer, GlaxoSmithKline, AstraZeneca, Novartis, Chiesi, and Merck. Funding : During the development of these guidelines, the IPCRG received unrestricted educational grants from Altana, AstraZeneca, Boehringer Ingelheim, EAMG, GlaxoSmithKline, Merck Sharp and Dohme, Mitsubishi Pharma, Novartis, UCB Pharma and Zambon. These funds were used for the purpose of funding face-to face-meetings and also to support a secretariat. Funding Information: Professor Chris van Weel has no shares in pharmaceutical companies. He has never personally received an honorarium from the pharmaceutical industry for speaking or advisory panel work. His Department of General Practice, Radboud University Medical Centre, Nijmegen, the Netherlands, has received since 1985, unrestricted research grants from GSK, AZ, Bayer, Boehringer Ingelheim, Novartis, Pfizer and Pharmacia. As the president-elect of the World Organisation of Family Doctors (Wonca) he has been involved in respiratory educational and development activities for which Wonca has been the recipient of unrestricted grants and honoraria from Boehringer Ingelheim and Altana. ",
year = "2006",
month = feb,
doi = "10.1016/j.pcrj.2005.11.003",
language = "English (US)",
volume = "15",
pages = "48--57",
journal = "Asthma in General Practice",
issn = "1471-4418",
publisher = "Primary Care Respiratory Society UK",
number = "1",
}